Despite the failure of traditional monoclonal drugs to improve the outcomes of HER2-Low patients in pivotal clinical trials [25], the recent DESTINY-Breast 04 trial has demonstrated HER2-Low breast cancer as a distinct clinical subgroup that can be targeted by novel ADCs treatment [7,26]. Here, ERBB2 is linked to breast cancer.